Trastuzumab Emtansine

證據等級: L5

預測適應症: 4 個

Trastuzumab Emtansine: From HER2-Positive Breast Cancer to Normal Breast-like Subtype of Breast Carcinoma

One-Sentence Summary

Trastuzumab emtansine (T-DM1, marketed as Kadcyla) is an antibody-drug conjugate approved internationally for HER2-positive breast cancer. The TxGNN model predicts it may be effective for normal breast-like subtype of breast carcinoma, but this direction is currently supported by only 1 clinical trial and no published literature, and the mechanistic link to this specific molecular subtype is weak.

Quick Overview

Item	Content
Original Indication	HER2-positive (HER2+) breast cancer (Kadcyla)
Predicted New Indication	Normal breast-like subtype of breast carcinoma
TxGNN Prediction Score	99.82%
Evidence Level	L4
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank. Based on known information, trastuzumab emtansine is an antibody-drug conjugate (ADC) that links trastuzumab, a monoclonal antibody targeting HER2, to DM1, a maytansinoid microtubule inhibitor. Its efficacy depends on HER2 overexpression (IHC3+/FISH+) in tumor cells, and it is currently used under the brand Kadcyla for HER2-positive breast cancer.

"Normal breast-like" is a PAM50 intrinsic molecular subtype classification, defined by gene-expression profiling rather than HER2 receptor status. This is a different classification axis from HER2 positivity, which is the actual determinant of T-DM1 activity. According to the evidence pack's own mechanistic assessment, the link between T-DM1 and the normal-like subtype is "indirect and unclear," since normal-like tumors are not defined by, and do not reliably correlate with, HER2 overexpression.

As a result, while the TxGNN prediction score is very high (99.82%), the underlying biological rationale is weaker than for HER2-status-based predictions. This is reflected in the low evidence level (L4) and the single supporting trial, which only broadly addresses anti-HER2 therapy in HER2+ breast cancer without specifically confirming a T-DM1 arm or normal-like subtype enrollment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06348134	Phase 2	Recruiting	74	Evaluates efficacy and safety of anti-HER2-based therapy (neoadjuvant to adjuvant) in Nigerian women with HER2+ breast cancer; does not confirm a specific T-DM1 arm or normal-like subtype focus (relevance grade B).

Literature Evidence

Currently no related literature available

Finland Market Information

This drug is currently not marketed in Finland (未上市), and no market authorization records are available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (antibody-drug conjugate with a cytotoxic maytansinoid payload, DM1)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (normal breast-like subtype) has a very high TxGNN score but a weak and indirect mechanistic basis, minimal clinical trial support (1 trial, relevance grade B), and no supporting literature — insufficient to advance. Notably, other predicted indications for this drug (PR-positive and PR-negative breast cancer) show much stronger evidence (L1–L2, multiple direct T-DM1 trials and literature) but largely overlap with the drug's existing HER2-positive breast cancer indication rather than representing genuine repurposing.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently a blocking data gap
DrugBank mechanism of action (MOA) data to strengthen mechanistic-relevance analysis
Confirmation of whether any T-DM1 trials specifically enroll or stratify by PAM50 normal-like subtype
Additional literature search specific to T-DM1 and normal-like/basal molecular subtypes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.